Alexandria Real Estate Equities, Inc. is a real estate investment trust (REIT) formed in 1994 that owns, operates, and develops Class A/A+ laboratory and office properties for the life science industry. The company focuses on collaborative Megacampus ecosystems in major North American innovation clusters, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, the Research Triangle, and New York City. Its tenant base includes multinational pharmaceutical companies, biotechnology firms, medical device manufacturers, academic and medical research institutions, and U.S. government research agencies. Alexandria also maintains a venture capital platform to invest in privately held and publicly traded life science companies. The company’s strategy involves the acquisition, development, and redevelopment of generic, reusable laboratory spaces to support tenant growth and innovation.

Summarised from the company's own disclosures, fiscal year ended Jan 2026

Industry REIT - Specialty Homepage are.com
Sector Real Estate IR page investor.are.com/corporate-profile/default.aspx
Tags
life science real estate, laboratory facilities, megacampus ecosystems, venture capital, biotechnology, pharmaceuticals, medical devices, research institutions, property development, property redevelopment, Megacampus, ARE, Alexandria Advantage
Press page —

Metrics

Valuation  
Market cap $ 8.106B
Market cap (USD) $ 8.106B
P/E -5.64
PEG —
P/BV 0.55
P/S 2.94
P/OCF 6.82
P/FCF 5.73
Dividend yield 6.1%
Turnover / mcap —
Returns  
ROE -8.6%
ROI -5.1%
ROIC 1.5%
Profit margin -47.2%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 87.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score -26.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 1999 FY 1998
Revenue 3.027B 3.116B 2.886B 2.589B 2.114B 1.886B 1.531B 1.327B 1.128B 921.706M 843.474M 726.877M 631.151M 586.073M 573.443M 487.303M 480.14M 460.668M 405.36M 310.779M — —
Net profit -1.43B 322.949M 103.639M 521.66M 571.247M 770.959M 363.165M 379.312M 169.093M -65.901M 144.217M 106.778M 135.317M 99.908M 132.306M 139.022M 141.648M 122.869M 93.724M 73.416M 22.053M 19.403M
Free cash flow 1.414B 1.505B 1.631B 1.294B 1.01B — — — — — — — — — — — -240.177M -308.138M — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 1999 FY 1998
Share price 48.94 97.55 126.77 145.67 222.96 178.22 161.58 115.24 130.59 111.13 90.36 88.74 63.62 69.32 68.97 73.26 64.29 37.52 92.23 98.55 — —
Price performance 12m -0.5 -0.23 -0.13 -0.35 0.25 0.1 0.4 -0.12 0.18 0.23 0.02 0.39 -0.08 0.01 -0.06 0.14 0.71 -0.59 -0.06 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 0.00 272M 346M 435M 407M 383M 507M 361M
Cash and deposits (USD) 125M 254M 234M 190M 569M 361M 825M 618M 552M 549M
Right-of-use assets (USD) — — 0.00 265M 336M 474M 558M 516M 764M 698M
Cash flow detail
Operating cash flow (USD) 393M 450M 570M 684M 883M 1.01B 1.29B 1.63B 1.5B 1.41B
Dividends paid (cash effect) (USD) -240M -312M -381M -447M -533M -656M -758M -847M -899M -911M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -50.1M -208M
Interest paid (cash effect) (USD) -84.9M -112M -127M -146M -161M -139M -63.2M -46.6M -160M -204M
Share-based compensation (USD) 25.4M 25.6M 35M 43.6M 43.5M 48.7M 57.7M 82.9M 59.6M 41.1M
Income detail
Total comprehensive income (USD) -93.6M 239M 392M 405M 830M 654M 657M 286M 480M -1.2B
Comprehensive income to owners (USD) -110M 214M 369M 364M 774M 571M 508M 109M 293M -1.41B
Provision for credit losses (USD) — — — — — — — — — 295,000
Reported Jan 31, 2017 Jan 30, 2018 Apr 30, 2019 Feb 4, 2020 Apr 26, 2021 Apr 25, 2022 Jan 27, 2025 Jan 27, 2025 Jan 27, 2025 Jan 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

10/29/2026

Download the PDF version PDF Format (opens in new window)

PASADENA, Calif., Oct. 29, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation clusters, today celebrates the 20th anniversary of the Prix Galien USA in New York City and its longstanding strategic partnership with the Galien Foundation, a premier global organization dedicated to recognizing and advancing scientific innovation that improves human health. For more than two decades, Alexandria has been a driving force in the creation and growth of New York City's commercial life science ecosystem, bringing together mission-critical infrastructure, strategic venture capital and world-class talent to catalyze and grow innovative life science companies.

At today's Galien Forum USA, Alexandria will lead a panel discussion on the Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative, titled "Cracking the Code of Depression: The MAP-D Initiative." The panel will feature leading experts in neuroscience research, patient care, policy and drug development including Amit Etkin, MD, PhD, founder and chief executive officer of Alto Neuroscience; Steve Hoffmann, senior vice president and chief preclinical officer of the Foundation for the National Institutes of Health (FNIH); Husseini Manji, MD, professor at Oxford University, chair of the UK Government Mental Health Goals Program and former global head of neuroscience at Johnson & Johnson; and Mark Mintun, MD, group vice president of neuroscience research and development at Eli Lilly and Company. The panel will be co-moderated by Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments and Lynne Zydowsky, PhD, chief of science of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments.

As the FNIH's founding strategic partner on the MAP-D initiative, Alexandria provided the first funding and helped secure the cross-sector support required to launch the pioneering public-private partnership. In June 2026, the MAP-D initiative completed its critical design phase and began advancing toward a first-of-its-kind longitudinal clinical study integrating biological, clinical, neuroimaging, digital and patient-reported data to generate one of the most comprehensive depression research datasets ever assembled. The three-year pilot will leverage advanced artificial intelligence models to identify relationships between biological markers and patient outcomes. Ultimately, the MAP-D initiative aims to establish a scalable precision medicine framework for depression to accelerate scientific discovery and extend its impact beyond depression to other serious mental illnesses, with the potential to serve as a defining blueprint for precision mental health over the next decade.

"For 20 years, the Prix Galien USA has recognized outstanding scientific achievements that have changed the course of human health, and Alexandria is deeply proud of our founding partnership with the Galien Foundation and our shared commitment to advancing life-changing innovation," said Mr. Marcus. "Driven by our noble mission to advance human health, Alexandria Venture Investments (AVI) is the second most active institutional life science investor in NYC, providing strategic capital and expertise to companies pursuing novel approaches across oncology, neuroscience, gene therapy and AI-enabled drug discovery. Our first investment, Intra-Cellular Therapies, Inc. (ITCI), became one of the city's most compelling biotechnology success stories, culminating in its $14.6 billion acquisition by Johnson & Johnson in 2025."

Alexandria's venture investment leadership in NYC dates back to 2002, when AVI participated in ITCI's Series A financing, beginning a longstanding strategic and financial relationship with Sharon Mates, PhD, founder, former chairman and chief executive officer of ITCI. ITCI advanced category-defining neuroscience research from discovery through clinical development, went public and grew into a leading biopharmaceutical company with the commercialization of CAPLYTA®, a treatment for schizophrenia and bipolar depression. Dr. Mates led the company from founding through its historic exit, demonstrating a remarkable commitment to ITCI and the NYC life science ecosystem. Mr. Marcus served on ITCI's board of directors from 2006 through its acquisition.

In October 2025, AVI participated in the oversubscribed $101 million Series A financing of NYC-based Nilo Therapeutics (Nilo), alongside leading life science investors and the Gates Foundation. Nilo represents a new generation of innovative companies emerging from NYC's world-class life science ecosystem. The company is developing a novel class of medicines designed to harness the body's neural circuits to regulate immune function and inflammation, with the potential to address a broad range of immune-mediated diseases.

Eikon Therapeutics (Eikon), an AVI portfolio company with its East Coast operations at the Alexandria Center® for Life Science – NYC, is advancing a pipeline of oncology medicines under the leadership of renowned pharmaceutical executive Roger Perlmutter, MD, PhD. In February 2026, Eikon completed an upsized $381 million initial public offering, marking a significant milestone and demonstrating the continued growth of an AVI-backed company within Alexandria's NYC ecosystem.

**About Alexandria Real Estate Equities, Inc.

**Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. Founded in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. For more information, please visit www.are.com

.

Forward-Looking Statements 

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the development and potential therapeutic applications of medicines being pursued by Alexandria Venture Investments' portfolio companies; the anticipated timing, launch, scope, duration and conduct of the MAP-D initiative and its pilot phase; the use of artificial intelligence and other data-analysis methods in the initiative; the initiative's ability to identify relationships between biological markers and patient outcomes, inform more personalized treatment approaches, accelerate scientific discovery and improve patient outcomes; and Alexandria's role in and support of the initiative, its collaboration with the FNIH and the anticipated impact and benefits of such support and collaboration. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the availability and timing of funding; the receipt of required approvals; participant recruitment and retention; the performance of collaborators; scientific, technical and operational challenges; and changes in the initiative's design, scope, timing or cost, as well as the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update or revise any forward-looking statement, except as required by law. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.

Table of Contents

September 30, 2026

COMPANY HIGHLIGHTS

Page

Page

Alexandria's Mission and Cluster Model ..............................................

iii

EARNINGS PRESS RELEASE

Third Quarter Ended September 30, 2026 Financial and

Operating Results ................................................................................

1

Consolidated Statements of Operations ..........................................

10

Guidance ...................................................................................................

4

Consolidated Balance Sheets ............................................................

11

Dispositions and Sales of Partial Interests ..........................................

8

Funds From Operations and Funds From Operations per Share

12

Earnings Call Information and About the Company ...........................

9

SUPPLEMENTAL INFORMATION

Company Profile .......................................................................................

15

External Growth / Investments in Real Estate

Investor Information .................................................................................

09/28/2026

Download the PDF version PDF Format (opens in new window)

PASADENA, Calif., Sept. 28, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) today announced the closing of its amended and restated $5.0 billion unsecured senior line of credit, a strategic extension that further strengthens the company's long-term financial flexibility and reflects the enduring support of its longstanding, trusted banking partners. The amendment extends the maturity of the facility to January 2032 and reduces the applicable borrowing margin, reinforcing Alexandria's disciplined and proactive management of its strong and flexible balance sheet. The amended agreement became effective on September 24, 2026.

The amended agreement extends the maturity date of Alexandria's $5.0 billion unsecured senior line of credit from January 22, 2030 to January 22, 2032, assuming the company exercises its rights to extend the maturity date twice by an additional six months for each exercise, subject to certain conditions. The extension preserves Alexandria's substantial revolving credit capacity and advances the company's longstanding financial strategy to maintain significant liquidity, prudently ladder debt maturities, and preserves access to diverse sources of capital, providing critical financial capacity to execute across market cycles.

The amended agreement also reduces the applicable borrowing rate to SOFR plus 0.725%, representing an 11-basis-point reduction from the currently applicable rate of SOFR plus 0.835%.

"The successful extension of our $5.0 billion unsecured senior line of credit underscores the strength of our mission-critical relationships with our banking partners and their continued confidence in and longstanding support of Alexandria," said Marc E. Binda, chief financial officer and treasurer of Alexandria Real Estate Equities, Inc. "Extending the maturity to 2032 while reducing our borrowing margin represents another consequential execution by our best-in-class team to further strengthen our balance sheet, prudently manage our long-term cost of capital, and maintain significant liquidity and financial flexibility. These enduring financial strengths position Alexandria to execute our highly differentiated, mission-driven business model with discipline and conviction, and capitalize on strategic opportunities through evolving market cycles."

Citibank, N.A. serves as administrative agent under the amended agreement. Citibank, N.A., BofA Securities, Inc., JPMorgan Chase Bank, N.A., Goldman Sachs Bank USA, RBC Capital Markets, Banco Bilbao Vizcaya Argentaria, S.A. New York Branch, Mizuho Bank, Ltd., Sumitomo Mitsui Banking Corporation, TD Bank, N.A., The Bank of Nova Scotia, Truist Securities, Inc. and U.S. Bank National Association serve as joint lead arrangers; and Citibank, N.A., BofA Securities, Inc., JPMorgan Chase Bank, N.A., Goldman Sachs Bank USA and RBC Capital Markets serve as joint bookrunners.

**About Alexandria Real Estate Equities, Inc.

**Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle and New York City. For more information, please visit www.are.com

.

**Forward-Looking Statements

**This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding Alexandria's corporate responsibility initiatives, strategic investments, partnerships and support of charitable and community organizations; Alexandria's role in supporting tenants and companies in which it invests that are engaged in research and development in hematology and oncology; and the anticipated impact or benefits of these investments, partnerships and support, including the expected impact of the missions, programs and initiatives of the charitable and community organizations Alexandria supports. These forward-looking statements are based on Alexandria's present intent, beliefs, or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.

Prompts

Alexandria Real Estate Equities, Inc. (ticker ARE), listed in United States.

ETFs Holding Alexandria Real Estate Equities, Inc.

ETF Weight in ETF Shares Market value As of
SRHR 3.31% 35,000 $ 1.801M Jul 31, 2026
CVAR 2.12% 17,686 $ 909.945K Jul 31, 2026
REIT 1.56% 17,125 $ 878.341K Aug 31, 2026
BLDG 1.26% 16,499 $ 848.874K Jul 31, 2026
EPSV 1.20% 1,649 $ 72.292K Nov 13, 2026
NXTE 1.18% 12,844 $ 678.805K Jun 30, 2026
MKTN short -1.13% -22,776 $ -1.204M Jun 30, 2026
EPMV 1.00% 1,092 $ 47.873K Nov 13, 2026
DWSH short -0.99% -1,450 $ -61.451K Nov 17, 2026
JPRE 0.96% 107,564 $ 4.559M Nov 17, 2026
DVND 0.90% 9,010 $ 476.179K Jun 30, 2026
VGSR 0.79% 78,020 $ 4.123M Jun 30, 2026
IYRI 0.59% 37,294 $ 1.77M Sep 30, 2026
DFAR 0.47% 906,842 $ 40.173M Nov 12, 2026
BTAL short -0.41% -21,758 $ -1.15M Jun 30, 2026
USAF 0.32% 1,057 $ 55.862K Jun 30, 2026
FMDE 0.25% 345,382 $ 18.253M Jun 30, 2026
REMC 0.20% 131 $ 6,923.35 Jun 30, 2026
FLDZ 0.20% 155 $ 8,191.75 Jun 30, 2026
DFGR 0.19% 174,261 $ 7.72M Nov 12, 2026
JAVA 0.17% 291,098 $ 12.337M Nov 17, 2026
CAPE 0.15% 6,903 $ 364.824K Jun 30, 2026
FTHI 0.12% 69,979 $ 3.046M Nov 16, 2026
INRO 0.08% 11,480 $ 499.724K Nov 16, 2026
JUSA 0.02% 3,730 $ 158.077K Nov 17, 2026
VOXP 0.01% 12 $ 617.40 Jul 31, 2026
HCMT 0.01% 1,090 $ 56.081K Jul 31, 2026
ACVF 0.01% 230 $ 11.834K Jul 31, 2026
CSHP 0.00% 128 $ 5,571.84 Nov 16, 2026
IALT short 0.00% -996 $ -43.356K Nov 16, 2026
CORO 0.00% 99 $ 4,309.88 Nov 16, 2026
GSPY 0.00% 607 $ 26.423K Nov 17, 2026